Immunome (IMNM) insider buying
6 open-market purchases of IMNM by Immunome's executives and directors since June 2025, worth $2M in total, from SEC Form 4 filings.
The most recent: Jean Jacques Bienaime bought $21,550 on March 11, 2026.
The biggest buyer over the period is Clay B Siegall: 3 purchases, $1M.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 1 | $21,550 |
| 2025 | 5 | $2M |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Clay B Siegall | 3 | $1M |
| Philip Tsai | 1 | $204,900 |
| Jean Jacques Bienaime | 2 | $68,450 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Mar 11, 2026 | Jean Jacques Bienaime |
1,000 | $21.55 | $21,550 | Form 4 |
| Dec 30, 2025 | Clay B Siegall |
4,729 | $21.15 | $100,018 | Form 4 |
| Dec 19, 2025 | Clay B Siegall |
7,278 | $20.48 | $149,053 | Form 4 |
| Dec 19, 2025 | Philip Tsai |
10,000 | $20.49 | $204,900 | Form 4 |
| Dec 18, 2025 | Clay B Siegall |
46,511 | $21.50 | $999,986 | Form 4 |
| Jun 3, 2025 | Jean Jacques Bienaime |
5,000 | $9.38 | $46,900 | Form 4 |
Questions
Are Immunome insiders buying the stock?
6 open-market purchases of IMNM by Immunome's executives and directors since June 2025, worth $2M in total, from SEC Form 4 filings. The most recent: Jean Jacques Bienaime bought $21,550 on March 11, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Immunome's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.